CompletedNCT01272986OP512011Updated Mar 8, 2011

Trial of Screening for ALOA-IgG AtheroAbzyme Test

A Phase 3 interventional study of ALOA IgG-Elisa and ALOA IgG-AtheroAbzyme in Myocardial Ischemia and Acute Coronary Syndrome, sponsored by Omicron Pharmaceuticals. Completed at 1 site in Lebanon. Per ClinicalTrials.gov, last updated 2011-03-08.

Sponsored by Omicron Pharmaceuticals · Phase 3, Interventional, and Diagnostic

Phase: Phase 3
Study type: Interventional
Enrollment: 100
Allocation: Non-randomized
Sex: All

Study summary

This is a trial of screening for ALOA-IgG AtheroAbzyme Test comparing healthy, asymptomatic myocardial ischemic and acute coronary syndrome patients.

Conditions studied

Myocardial Ischemia
Acute Coronary Syndrome

Browse trials for

Keywords

Determination of the level of oxidised LDL by measuring the level of IgG in Blood

In context

Acute Coronary Syndrome

1,461 studies on the registry are indexed under Acute Coronary Syndrome; 267 are open to participants now.

This study's planned enrollment of 100 is below the median of 200 across 869 interventional studies indexed under Acute Coronary Syndrome.

Browse Acute Coronary Syndrome studies →

Lead sponsor

Omicron Pharmaceuticals is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible: All
Accepts healthy volunteers: Yes

Inclusion criteria

Healthy patients
High Risk patients or Asymptomatic myocardial Ischemic patients
Acute Coronary Syndrome patients

Exclusion criteria

Exclusion Criteria:

None

Study design

Phase: Phase 3
Primary purpose: Diagnostic
Allocation: Non-randomized
Intervention model: Parallel assignment
Masking: None (open label)
Enrollment: 100 participants (estimated)

Study arms

Placebo comparator
Healthy patients
Device: ALOA IgG-Elisa · Device: ALOA IgG-AtheroAbzyme
Active comparator
Asymptomatic myocardial Ischemic patients
Device: ALOA IgG-Elisa · Device: ALOA IgG-AtheroAbzyme
Active comparator
Acute Coronary Syndrome Patients
Device: ALOA IgG-Elisa · Device: ALOA IgG-AtheroAbzyme

Interventions

DeviceALOA IgG-Elisa
measurement of IgG Level in blood
DeviceALOA IgG-AtheroAbzyme
measurement of IgG in blood

What researchers measure

Primary outcomes

Measuring the degree of oxidized low-density lipoprotein (LDL) by ALOA- IgG AtheroAbzyme in healthy and cardiovascular disease patients
Time frame: Three months

Study locations

1 site

Bahman Hospital
Beirut, Haret Hriek, Lebanon

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Mar 8, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT01272986
Lead sponsor: Omicron Pharmaceuticals
First posted: Jan 10, 2011
Start date: Jan 2011
Primary completion: Mar 2011
Completion: Mar 2011
Last update: Mar 8, 2011

Study contacts

Malek Mohamad

principal investigator · Bahman Hospital

Oversight

Data monitoring committee: Yes

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Acute Coronary Syndrome→

Other studies from this sponsor

Omicron Pharmaceuticals

Start the discussion